Nexgel Inc (NXGL) — Titan Protect Analysis

NXGL

Nexgel Inc

Healthcare · ·

$0.56

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$6M

Total market value of the company

Trailing P/E

N/A

Forward P/E

1.52

Based on estimated future earnings — lower means cheaper

Rev Growth

-8.1%

Year-over-year revenue change

Profit Margin

-26.3%

How much profit the company keeps from each dollar of revenue

ROE

-52.7%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$2.00

+257% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 1 analysts covering this stock

About Nexgel Inc

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also develops NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm

https://nexgel.com

Country: United States Employees: 19 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.335

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0469

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.530

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-47.5%

Historical annualised return based on price data

Max Drawdown

-89.7%

Largest peak-to-trough decline — the worst it has been

HMM State

CRISIS

Elevated risk detected — extreme caution warranted

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.74

Less volatile than the market — more defensive

52W High

$2.89

81% below the year high

52W Low

$0.48

17% above the year low

Avg Volume

395,820

Average daily shares traded — higher means easier to buy and sell

Short Ratio

1.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.40

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

63.14

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

39.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-43.4%

Profit from core operations before interest and tax

Free Cash Flow

$-1,099,250

Negative — the business is spending more than it generates

Revenue (TTM)

$11M

Total revenue over the last 12 months

Net Income

$-3,000,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$2.00

Target Median

$2.00

Target Low

$2.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go